Automated Insulin Delivery Systems: Impact on Clinical Practice, Discontinuation, Rejection, and Reasons for Not Managing Well
Authors' conclusion
Despite increasing user rates of AID systems, a significant proportion reports problems in managing this technology or aborting its use.
Study context
- Population
- Health care professionals and people with diabetes from Germany, Austria, Switzerland and Spain (dt-report 2025, end of 2024)
- Participants
- 1,294 vs 2,535
- Exposure
- Health care professionals (HCPs) vs people with diabetes (PWD)
- HCPsn = 1,294
- PWDn = 2,535
- Outcome
- AID relevance, indications, rejection, discontinuation and satisfaction
Methodological detailsmultinational, online survey
- Multinational
- Online survey
Main finding
As reported in the abstract
PWT1D seen as candidates for automated insulin delivery (AID) therapy
90%
PWT2D on intensified insulin therapy considered likely to benefit from AID
55%
Eligible PWD who rejected AID (citing device burden and usability concerns)
22%
Discontinuation rate reported by HCPs
8%
Observational data: associations, not effects.
Original publication
Automated Insulin Delivery Systems: Impact on Clinical Practice, Discontinuation, Rejection, and Reasons for Not Managing Well. J Diabetes Sci Technol. Published 7 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →